Compare GPI & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPI | IRTC |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1997 | 2016 |
| Metric | GPI | IRTC |
|---|---|---|
| Price | $325.03 | $116.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $447.14 | $197.92 |
| AVG Volume (30 Days) | 141.6K | ★ 509.7K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 10.85 | N/A |
| Revenue | ★ $11,123,721,000.00 | $747,138,000.00 |
| Revenue This Year | $3.41 | $19.60 |
| Revenue Next Year | $3.10 | $15.94 |
| P/E Ratio | $29.52 | ★ N/A |
| Revenue Growth | 2.17 | ★ 26.24 |
| 52 Week Low | $292.44 | $108.81 |
| 52 Week High | $488.39 | $210.01 |
| Indicator | GPI | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 47.20 |
| Support Level | $311.31 | $112.65 |
| Resistance Level | $352.78 | $127.50 |
| Average True Range (ATR) | 12.49 | 6.01 |
| MACD | -2.71 | -0.02 |
| Stochastic Oscillator | 40.61 | 39.43 |
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.